Early functional SARS-COV-2 specific T cell response may prevent severe infection

Humoral and cellular adaptive immunity are two immune mechanisms that act against pathogens. Humoral immunity is mediated by antibodies, while cellular immunity does not involve antibodies and is, instead, facilitated by T cells. Studying how these immune mechanisms mediate SARS-CoV-2 infections could be beneficial in controlling the progression of the disease. However, their roles in viral control or disease pathogenesis is not fully understood and only a few studies have thoroughly monitored COVID-19 patients longitudinally, especially during the acute phase of infection.

To fill this knowledge gap, the team of researchers at Duke-NUS investigated the changes in virological and immunological parameters in 12 patients with symptomatic acute SARS-CoV-2 infection from onset of the disease to recovery or death.

"We found that patients who control SARS-Cov-2 infection with only mild symptoms are characterised by an early induction of IFN-γ secreting SARS-CoV-2 specific T cells. The amount of humoral response, however, does not predict the level of COVID-19 disease severity," said Dr Anthony Tanoto Tan, Senior Research Fellow at the Duke-NUS' Emerging Infectious Diseases (EID) programme and the co-author of this study.

"Our data supports the idea that SARS-CoV-2 specific T cells play an important role in the rapid control of viral infection and eventual clearance of the disease," added Dr Martin Linster, Senior Research Fellow with Duke-NUS' EID programme and the co-author of this study.

This work is a continuation of the team's previous publication in Nature, where they analysed SARS-CoV-2 specific T cell response in COVID-19 patients at convalescence. In this study, they have expanded the analysis to the full timeline of SARS-CoV-2 infection from onset to outcome.

"It is time that T cell monitoring should be considered in providing a comprehensive understanding of the immune response against SARS-CoV-2. This would also mean that a vaccine will likely be more effective if a holistic induction of both antibodies and T cells occurs," said Professor Antonio Bertoletti, from Duke-NUS' EID programme, who is the corresponding author of this study.

"This important study furthers our understanding of the immune response against SARS-CoV-2. It has far-reaching implications including on COVID-19 vaccine design and the subsequent monitoring of vaccine response," said Professor Patrick Casey, Senior Vice-Dean for Research at Duke-NUS.

The team is now studying more symptomatic COVID-19 patients with varying disease severity to further validate their findings.

Anthony T Tan, Martin Linster, Chee Wah Tan, Nina Le Bert, Wan Ni Chia, Kamini Kunasegaran, Yan Zhuang, Christine YL Tham, Adeline Chia, Gavin JD Smith, Barnaby Young, Shirin Kalimuddin, Jenny GH Low, David Lye, Lin-Fa Wang, Antonio Bertoletti.
Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients.
Cell Reports,, 2021. doi: 10.1016/j.celrep.2021.108728

Most Popular Now

Scientists identify 'immune cop' that detects SARS…

Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified the sensor in human lungs that detects SARS-CoV-2 and signals that it's time to mount an ...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

New England Journal of Medicine publishes COVID-19…

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of th...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

Bayer transforms pharma business through breakthro…

At its virtual Pharma Media Day, Bayer presented exciting progress in transforming its pharmaceutical business with breakthrough innovation in healthcare that will signif...

Valneva in advanced discussions with European Comm…

Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, announced it is in advanced discussions with the...

Metformin use reduces risk of death for patients w…

Use of the diabetes drug metformin - before a diagnosis of COVID-19 - is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, acco...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

Vir Biotechnology and GSK announce NHS-supported A…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients...

COVID-19 has multiple faces

According to current studies, the COVID-19 disease which is caused by the SARS-CoV-2 coronavirus comprises at least five different variants. These differ in how the immun...